Introduction
Metastatic melanoma is a fatal cancer, with rapidly increasing incidence among Caucasians, for which there is no eective treatment (Henderson et al., 1991) . The mechanism by which normal human melanocytes become malignant in vivo is still little understood. The loss of a tumor suppressor gene residing in chromosomal band 9p21?p22 is thought to be a primary genetic transforming event, because it is common in melanocytes from atypical nevi, primary and metastatic melanomas (Cowan and Francke, 1991; Cowan et al., 1988; Holland et al., 1994; Walker et al., 1994) . Genetic studies suggest that the cyclin-dependent kinase inhibitor (CDI) p16
INK4 is one of the aected genes at this site Nobori et al., 1994) because inactivation mutations in the INK4 locus were detected in several individuals from melanoma prone families (Koh et al., 1995; Liu et al., 1995; Reymond and Brent, 1995) reviewed in reference (Cannon-Albright et al., 1996; Kamb, 1994) . However, there is basis to assume that other regulatory proteins contribute to the development of melanomas since mice carrying a targeted deletion of the INK4a locus that eliminates p16 INK4 developed spontaneous non-melanocytic tumors at an early age, were highly sensitive to carcinogenic treatments but did not develop melanomas (Serrano et al., 1996) .
Human melanoma cells from advanced primary (such as Breslow depth above *2.0 mm) or metastatic lesions, are less dierentiated (or not at all) compared to normal melanocytes and are not dependent on external growth factors, required for their normal counterparts. The pigment cell mitogenic peptides identi®ed so far are FGFs (Fibroblast Growth Factors), Hepatocyte Growth Factor/Scatter Factor (HGF/SF), Mast-cell Growth Factor (MGF, known also as Kit ligand, stem-cell growth factor, and steel factor) and the neuropeptides endothelin-1, 2 and 3 (ET-1, ET-2, ET-3), (reviewed by Halaban, , 1996 . The autocrine growth of melanoma cells is conferred, at least in part, by ectopic expression of growth factors (Balentien et al., 1991; Easty et al., 1995; Halaban, 1992) . Of all the melanocyte growth factors listed above, bFGF (basic FGF) plays the most decisive role in the progression of normal human melanocytes to melanomas (Becker et al., 1989 (Becker et al., , 1992 Halaban et al., 1987 Halaban et al., , 1988 Halaban et al., , 1991 . The abnormal expression of bFGF/FGF2 is detected already in melanocytes in atypical nevi in situ (Albino et al., 1991; Reed et al., 1994; Scott et al., 1991) , and has been observed in all melanoma cell lines tested. bFGF/ FGF2 causes constitutive activation of the receptors, which are expressed at normal levels (Becker et al., 1992; Halaban and Moellmann, 1993) . High expression of bFGF/FGF2 induces not only autonomous growth but also downregulation of melanocytic functions through suppression of microphthalmia, encoding a critical melanocyte-speci®c transcription factor (Dotto et al., 1989; Halaban et al., 1996) .
In spite of the fact that melanoma cells express multiple growth factors, it is still possible to arrest growth by interfering with the production or biological activity of bFGF. Melanoma cell proliferation in vitro is inhibited by: (a) synthetic bFGF peptides that span the receptor's ligand-binding domain and act as bFGF antagonists (Halaban et al., 1987) ; (b) internalized antibFGF or anti-phosphotyrosine antibodies (Halaban et al., 1987) ; and (c) anti-sense bFGF or bFGF-receptor mRNA (Becker et al., 1989 (Becker et al., , 1992 . These observations may indicate the importance of FGFs and their receptors in general, and bFGF acting through FGFR1 in particular, in the concerted action of synergistic factors regulating melanoma cell growth and fate.
One way to ®nd out whether activation of the FGF receptors in melanoma cells confers growth advantage on these cells is by permanently interfering speci®cally with this receptor family. The biological activities of FGFs are presumably mediated through binding to speci®c, high anity cell surface receptors. The binding induces dimerization of the receptors and activation of their intracellular tyrosine kinase domain via crossphosphorylation of tyrosine residues at designated sites (Fantl et al., 1993; Johnson and Williams, 1993; Lemmon and Schlessinger, 1994; Mohammadi et al., 1996; Schlessinger and Bar-Sagi, 1994; Yarden and Ullrich, 1988 (Fantl et al., 1993; Givol and Yayon, 1992; Johnson and Williams, 1993) . Normal and malignant melanocytes express predominantly FGFR1 (Becker et al., 1992; Halaban et al., 1991) although gene transcripts for FGFR4 were also detected preferentially in the malignant but not in the normal melanocytes (Easty et al., 1993) . Ectopic expression of a truncated receptor comprising the extracellular and transmembrane domains but lacking the intracellular kinase domain interferes with the function of wild-type receptor by blocking transphosphorylation (Amaya et al., 1993; Ueno et al., 1992 Ueno et al., , 1993 . Furthermore, cell transformation by FGF4 is suppressed by transduction with a truncated FGFR2, and to a lesser extent with FGFR1 (Li et al., 1994b) .
To test the role of uncontrolled expression of bFGF in malignant transformation of melanocytes we attempted to inhibit FGFR activity by transfection with a dominant-negative¯g mutant (dn¯g). We show that expression of such a dominant-negative receptor reduces the growth rate in culture and tumorigenic potential in vivo of NIH3T3 cells transformed with a 
Results
Expression of dominant-negative¯g mutant in spbFGFtransformed NIH3T3 suppress their tumorigenic phenotype
The ability of the pSVdn¯g construct expressing the truncated form of mouse fgfr1/¯g that lacks most of the tyrosine kinase domain to block the autocrine loop created by endogenous bFGF was ®rst tested in tumorigenic NIH3T3 ®broblasts transduced with a secreted form of bFGF fused to the immunoglobulin signal peptide (spbFGF) (Rogelj et al., 1988; Yayon and Klagsbrun, 1990b) . The hygromycin resistant spbFGF-NIH3T3 clones were monitored for pSVdn¯g expression by the high-anity binding assay with 125 I-labeled bFGF. Six clones, designated A2, A5, A6, B1, D1 and D2 showed greatly enhanced high-anity binding (21 ± 32-fold increase) compared with parental spbFGF-NIH3T3 or the original NIH3T3 ®broblasts (3 ± 5-fold increase) ( Figure 1a) . A chemical cross-linking study using DSS (disuccinimidyl suberate) with [ (Li et al., 1994b; Ueno et al., 1992) . Also exhibited in the parental NIH3T3 cells and less so in each of the six clones is a 135/150 kDa double band corresponding to the endogenous wild-type FGFRs on the cell surface ( Figure 1b , double arrow).
Kinase defective, either mutated or truncated are thought to exert their dominant negative phenotype through the formation of inactive heterodimers with their normal receptor counterparts. In order to address the capacity of the truncated receptor to undergo ligand-dependent homo-and hetero-dimerization we performed chemical cross linking of [ The spbFGF-NIH3T3 cells are highly transformed in vitro and tumorigenic in vivo (Yayon and Klagsbrun, 1990b) . The transformed phenotype is expressed, among other characteristics, as an enhanced rate of proliferation and a capacity to form rapidly growing tumors in nude mice (Yayon and Klagsbrun, 1990b) . The rate of proliferation of the six clones expressing dn¯g was reduced by 68% to 95% compared with that of spbFGF NIH3T3 cells (1.5 days vs 3.5 days population doubling time, comparing spbFGF cells to clones B1 and D1, and up to *11 days for clone D2, Figure 2a Expression of the dn¯g aected also the morphology of the spbFGF transformed ®broblasts (data not shown). Whereas the spbFGF-NIH3T3 cells are small and round cells, with refractive cell body and thin, long cytoplasmic extensions, forming large cell aggregates at high densities (Yayon and Klagsbrun, 1990b) , the dn¯g transformants remained attached, well spread, and appeared similar in morphology to the original NIH3T3 cells. The dn¯gD2 cells did not form aggregates at high cell densities, while dn¯gB1 cells did so, although to a lesser extent than the parental spbFGF NIH3T3 clone (not shown).
When injected into nude mice, the spbFGF-NIH3T3 ®broblasts grew rapidly as tumors that were visible within a week and became extremely large by the end of the second week to a point where the mice had to be sacri®ced ( Figure 3 ). In contrast, the dn¯gB1 cells grew slowly in vivo, needed almost 2 weeks for the generation of palpable tumors and about 5 weeks to produce intractable tumor mass. No palpable tumors were found within 2 weeks after injection of dn¯gD2 cells, expressing the highest levels of dn¯g. Out of six mice, only three in one experiment and four in another, developed slow growing tumors that were visible 3 weeks after injections, yielding intractable tumors 2 to 3 months later ( Figure 3 , as indicated). The tumorigenic pro®le and the kinetics of cell proliferation of dn¯gD2 and dn¯gB1 cells correlated negatively with the expression levels of the truncated FGFR. These results indicate that expression of the truncated¯g suppressed spbFGF-induced autocrine proliferation and malignant transformation.
Expression of dn¯g in melanoma cells
Since the pSVdn¯g construct appeared to be highly eective at suppressing the tumorigenic phenotype created arti®cially in NIH3T3 cells by ectopic expression of secreted bFGF, we went on to test its eect on human melanoma cells. While human melanoma cells aberrantly express endogenous bFGF, not detected in their normal melanocyte counterparts, they tend to express extremely low levels of FGFR protein (our unpublished results and see below). We used ®ve dierent lines of metastatic melanoma cells expressing bFGF, since they varied in their capacity to take up and express foreign DNA (our unpublished results). Several G418 clones from each of the melanoma cell lines were isolated, expanded and analysed for the expression of the dn¯g gene transcripts. Two rounds of RT ± PCR ampli®cation using oligo-dT, random primers and external and nested primers speci®c for the mouse gene (Table 1) , identi®ed clear amplimers with the expected size in only a limited number of the isolated clones (data not shown), suggesting a very low expression level of the transgene. Only clones isolated from the 586-mel melanoma line consistently expressed detectable levels of the dn¯g transcripts even without a need for a second round of ampli®cation (Figure 4a ), and were therefore chosen for further analysis.
Ampli®ed products of *1.1 kb corresponding to the dn¯g transcript were detected in the three clones 586-dn¯g3, 586-dn¯g12 and 586-dn¯g13 (Figure 4a , pSVdn¯g). Two clones, 586-dn¯g3 and 586-dn¯g13 expressed the highest levels of the ectopic gene mRNA while clone 586-dn¯g12 expressed markedly lower levels of the transcript. As expected, there were no dn¯g amplimers in the parental (586 mel) or the pSVneo transformed 586 mel cells ( Figure 4a , 586 and pSVneo), whereas b-actin was ampli®ed at similar levels in all ®ve cell lines indicating equal amounts of mRNA in each ampli®cation reaction (Figure 4a , bactin). Interestingly, performing RT ± PCR with nested primers speci®c for the human (host) FGFR1 produced ampli®ed products of the expected size (*306 bp) after 35 rounds of ampli®cation in the parental and pSVneo transduced 586 mel cells but not in any of the three dn¯g-expressing clones even after two rounds of 
Suppression of melanoma cell growth and tumorigenicity by dn¯g
Two of the dn¯g expressing clones (referred to as 586-dn¯g) possessed markedly suppressed basal growth rates (Figure 5a ) exhibiting population doubling times of *3 and *6 days (586-dn¯g10 and 586-dn¯g13, respectively) compared to 2 days for vector-transduced 586-pSVneo or parental cells, as calculated from the linear slope of the curves presented in Figure 5a . The growth rate of the other two clones, 586-dn¯g3 and 586-dn¯g12, however, was not signi®cantly aected. Moreover, the levels of the transduced truncated receptor as evident by both RT ± PCR and cross linking experiments (Figure 4 ) did not correlate well with the degree of growth suppression in vitro ( Figure  5a ). For example, clone 586-dn¯g3 expressed high levels of receptor and yet its growth rate was similar to that of the 586-pSVneo transfectants, and clone 586-dn¯g10 expressed low levels of transgene and yet exhibited reduced growth rate. The 586 mel melanoma cells are ®broblastic in morphology and amelanotic and expression of the dn¯g did not cause any changes in morphology or pigmentation as determined by inspecting the color of the cell pellets.
The dn¯g expressing melanoma cells shared a signi®cantly hampered capacity to form tumors in nude mice (Figure 5b ). Visible tumors were observed within 2 weeks of injection of pSVneo-transduced 586 cells, but none in the transformants. Toward the end of the 4th week, the tumor size of dn¯g-transduced clones was below that of the control 586-pSVneo cells and the number of tumors per injection sites was markedly Total RNAs (5 mg) from parental 586 mel (586), control transfectant 586-pSVneo (pSVneo) and 586-dn¯g-transduced clones (dn¯g 3, 12 and 13) were subjected to RT ± PCR ampli®cation using primers speci®c for b-actin, human FGFR1 or plasmid pSVdn¯g (as marked). The human FGFR1 mRNA was subjected to two rounds of ampli®cation, ®rst with external primers spanning a 1 kb region (25 cycles) and then with nested primers (35 cycles) speci®c for the human gene ( Table 1) . The 1 kb ampli®ed product from the ®rst reaction cannot be seen. The second round of ampli®cation with the nested primers produced the expected 306 bp products only in parental 586 mel and the pSVneo-transduced cells but not in cells transduced with the pSVdn¯g (clones 3, 12 and 13). Ampli®cation with primers speci®c for pSVdn¯g (Table 1) (Figure 5b) . Unexpectedly, the reduction in tumor growth rate and incidence was evident even in clones, such as 586-dn¯g12, whose growth in vitro was not signi®cantly altered ( Figure 5 , compare growth rate in (a) to tumorigenesis in (b)). This is in contrast to the observed tight inverse correlation between dn¯g expression and cell proliferation and tumor progression in genetically engineered ®broblasts. This anomaly might be due to the low and variable receptor expression levels in human melanoma derived cells. The observation that the truncated-mutant¯g is more eective in suppressing tumor growth in nude mice than proliferation in culture, suggests that serum supplemented medium facilitates growth in the absence of receptor activity.
Decrease in Src-family kinase activity by expression of the dominant-negative FGFR mutant in melanoma cells Stimulation of normal human melanocytes with bFGF induced a detectable, but relatively weak increase in tyrosyl phosphorylation and activation of the MAPK cascade when compared to that induced by HGF/SF (Hepatocyte Growth factor/Scatter factor) or the KIT ligand M/SCF (BoÈ hm et al., 1995) . Likewise, the general levels and pattern of tyrosyl phosphorylation in the parental and transduced clones visualized in Western blots probed with anti-phosphotyrosine were found to be similar (data not shown). In addition, MAPK kinase assays using MBP as a substrate (BoÈ hm et al., 1995), revealed extremely low levels of activity of this enzyme in parental and 586-mel derivative cell lines (data not shown). Reports implicating Src kinase in the FGFR signal transduction pathway in other cellular systems (Kremer et al., 1991; Landgren et al., 1995; Zhan et al., 1994) , prompted us to assess changes in the activity of this intracellular kinase. Src kinase activity was ®rst measured in resting and bFGF stimulated normal human melanocytes (Figure 6a ). HGF/SF was used as a positive control since, as mentioned before, this growth factor is a strong stimulator of normal human melanocytes and it also stimulates Src-kinase activity in A549 lung carcinoma cells (Ponzetto et al., 1994) and osteoclastic cells (Grano et al., 1996) . Src proteins were immunoprecipitated with an antibody recognizing the three family members, Src, Fyn and Yes (designated Src-2), and the immobilized immune complexes were subjected to a kinase reaction in the presence of [g-32 P]ATP using Raytide as a substrate. As shown in Figure 6a , bFGF or HGF/SF caused a 2.5-fold increase in Src-kinase activity in normal human melanocytes. The magnitude of the change in activity is similar to that observed in Src autophosphorylation in response to bFGF in lung endothelial cells (Landgren et al., 1995) , as well as Srcinduced kinase activity by HGF/SF in carcinoma and osteoclastic cells (Grano et al., 1996; Ponzetto et al., 1994) . Parallel assays employing member-speci®c antibodies against Src, Fyn or Yes, failed to detect any activity above control antibody (data not shown). Anti-Src2 Western immunoblotting of the Src-speci®c immune precipitates did not detect any *60 kDa reactive band, clearly visible in Src-2 precipitates, suggesting that these antibodies were not ecient at precipitating the target proteins (data not shown).
We went on to determine if Src kinase activity was aected by the expression of pSVdn¯g in the melanoma cells. Immune complex kinase assays employing Src-2 polyclonal antibodies revealed a 2 ± 3-fold reduction in kinase activity in all four 586-dn¯g clones compared to parental 586-mel and control transfectant 586-pSVneo (Figure 6b ). Again, parallel kinase assays on immunoprecipitates using the three speci®c antibodies, Src, Yes or Fyn, did not produce any measurable activity above background. Although in the experiments presented here the levels of basal kinase activity in the parental melanoma cells were 50-fold and 15-fold higher than that of unstimulated and growth factor-stimulated normal human melanocytes, respectively, additional quantitative assays are needed to establish an increase in Src-family kinase activity in the transformed cells.
The dierences in kinase activity between normal and malignant melanocytes and between parental and dn¯g-transduced melanoma cells could be due to variation in expression of Src-family of proteins rather than changes in enzymatic activity. We therefore compared the pattern and levels of Src-family proteins in these cell lines by Western blotting whole cell lysates with Src-2 or family-member speci®c antibodies. A doublet band migrating at the 60 ± 62 kDa range was visualized by probing the membrane with the Src-2 antibody reactive with Src, Fyn and Yes. The intensity levels and pattern of migration of the 60 ± 62 doublet band appeared similar in 586pSVneo and dn¯g-transduced melanoma cells (Figure 6c , aSrc-2, double arrow). However, the lower migrating form was more intense and the higher molecular weight species was less visible in the normal human melanocytes compared to melanoma cells (Figure 6c, aSrc-2, arrowhead) . The *60 kDa protein bands reactive with c-Src-speci®c antibodies was present at equal levels in all cell lines (Figure 6c , ac-Src, arrow), whereas the levels of ac-Yes reactive protein bands were slightly variable (Figure 6c , ac-Yes arrow). Western immunoblotting with Fynspeci®c antibodies produced a band of equal intensity in all cell lines but with dierent migration properties in normal melanocytes compared with the melanoma cell lines (Figure 6c, aFyn, arrow) . In normal human melanocytes c-Fyn migrated to a lower position in the polyacrylamide gel compared to the melanoma cell lines, reminiscent of the aSrc-2 staining (not seen in either c-Src or c-Yes blots), and suggesting dierences in the level of Fyn phosphorylation (Figure 6c, aFyn,  arrowhead) . Taken together, the immunoblotting data are consistent with the conclusion that reduction in Src-kinase activity in the dn¯g-transformed 586 mel cells cannot be attributed to a decrease in the expression levels of one or several family members. Similarly, the higher levels of Src-family kinase activity in melanoma cells compared to normal human melanocytes cannot be explained by a proportional increase in the expression of any of the Src-family kinases as shown before for c-Yes (Loganzo et al., 1993) .
Discussion
In the studies described here we investigated the tumorigenic potential of FGFR1 activated in murine ®broblasts transformed by a secreted form of bFGF (NIH3T3spbFGF) (Rogelj et al., 1988; Yayon and Klagsbrun, 1990b) , and in spontaneously arising human melanoma cells. Signi®cant suppression of tumorigenicity was observed by over-expression of the dominant-negative FGFR1 mutant in both cellular systems. Furthermore, in vivo suppression of tumor progression strongly implicates a critical role for bFGF in the development of melanomas via an autocrine loop mechanism, thereby providing an important target for intervention with the progression of this skin cancer. These results are in agreement with a recent report showing that signaling-defective, truncated FGFR1 and FGFR2 suppressed the in vitro transformed phenotype of FGF4-expressing NIH3T3 ®broblasts (Li et al., 1994b) . Our studies extend these published in vitro observations to ectopically transformed ®broblasts and to a naturally occurring tumor cell aberrantly expressing bFGF . Furthermore, our immune complex kinase assays suggest that Src-family kinase(s) is an important downstream target for activated FGFR1 in normal and malignant human melanocytes.
Melanomas, as well as melanocytes, express extremely low levels of endogenous FGF receptors (as determined by immunoprecipitation and immunoblotting experiments, our unpublished results). Neomycin resistant clones from only one out of ®ve melanoma cell lines expressed the transgene at levels detectable by either a single round of mRNA ampli®cation with RT ± PCR or by [ 125 I]bFGF binding to cell surface receptors. In some of the other clones we could detect the trangsene message only after a second round of RT ± PCR ampli®cation with nested primers. It is thus possible that most dn¯g expressing clones failed to grow in culture due to severe inhibition conferred by the negatively regulating FGFR1 expressed even at relatively low levels. It should also be noted that the endogenous receptor was downregulated in the dn¯g expressing melanoma clones.
Saturation and competition studies with [ 125 I]bFGF in NIH3T3spbFGF ®broblasts and 586 mel melanoma cells con®rmed that the expressed dn¯g construct was Dominant-negative FGFR1 suppresses melanoma growth A Yayon et al transported to the membrane and was capable of binding the ligand at high anity. Furthermore, the truncated receptor severely hindered the growth of these cells in vitro and their ability to form tumors in nude mice. It has been suggested that suppression of bFGF-induced autocrine transformation by the dominant-negative FGFR mutant is a result of competition for the ligand and the formation of inactive heterodimers between endogenous wild-type and ectopic truncated receptor (Li et al., 1994b) . The [ 125 I]bFGF binding data indicated that this is probably true for the NIH3T3spbFGF ®broblasts described here, and for the ®broblasts transformed with the secreted FGF4 reported before (Li et al., 1994b) . In both cases, in vitro cross-linking with [ 125 I]bFGF clearly detected the monomer, homodimer and heterodimer forms of the receptor. However, this may not be the only reason for growth inhibition of melanoma cells expressing the natural, non-secreted bFGF. Cross-linking the receptor with [ 125 I]bFGF clearly detected endogenous FGFR1 in the control pSVneo transformed 586 mel melanoma cells, but very little could be found in one dn¯g transformant (dn¯g2) and none in three other transformants (dn¯g3, dn¯g12, and dn¯g13). The mutant monomers, in contrast, were present at high levels in two transduced melanoma clones (dn¯g3 and dn¯g13), less so in one clone (dn¯g10) and not at all in a third one (dn¯g12). RT ± PCR analysis revealed that the transgene message was indeed transcribed at high levels in 586-dn¯g3 and 586-dn¯g13 and less so in 586-dn¯g12. More strikingly, we could not detect the endogenous, wild-type receptor in dn¯g-transduced melanoma cells even by the sensitive procedure of RT ± PCR ampli®cation with nested primers. These results suggest that the truncated mutant FGFR1 downregulated the expression of wild-type human FGFR1. The molecular basis for this downregulation could be indirect, such as through sequestration of endogenous bFGF. Previous studies showed upregulated cell surface expression of FGFR1 in pancreatic cell lines engineered to express low levels of the cytosolic 18 kDa, or nuclear targeted 22.5 kDa FGF2 isoforms, presumably by increasing the stability of FGFR1 gene transcript (Estival et al., 1996) . It is thus possible that the reverse is also true, i.e. sequestration of bFGF by binding to the truncated receptor induces downregulation of the endogenous receptor.
Signaling from the activated FGFR1 is mediated by the tyrosine kinase activity of the intracellular region. The intermediates so far identi®ed include phospholipase Cg (Mohammadi et al., 1991) , ERK1 and ERK2 (Bogoyevitch et al., 1994; Creuzet et al., 1995) , cortactin (Zhan et al., 1994) , Src (Landgren et al., 1995; Zhan et al., 1994) , Shc and a 90 kDa protein identi®ed as 80K-H (Goh et al., 1996; Klint et al., 1995) . However, although bFGF is a potent mitogen for normal human melanocytes that acts in synergy with dbcAMP or ET-1, the levels of induced tyrosyl phosphorylation and activation in response to this ligand are extremely low (as compared with HGF/SF or the Kit ligand SC/MGF), including that of ERK2 (BoÈ hm et al., 1995) . Although the autonomous growing melanoma cells described here expessed several tyrosyl phosphorylated proteins not detected in unstimulated normal melanocytes [as shown before (Funasaka et al., 1992; Zakut et al., 1993) ], their intensity was not decreased by the truncated, mutant receptor suggesting that they were not originally induced by the bFGF autocrine loop.
We demonstrate here that a downstream target for the activated FGFR1 is a Src-family kinase. The Src kinase activity was increased 2.5-fold in normal human melanocytes in response to bFGF (or HGF/SF) and was reduced up to 2.5-fold in dn¯g 586-mel transfectants compared to parental lines. The reduced Src-family kinase activity in the 586-dn¯g transfectants was not due to a parallel decrease in protein levels, suggesting downregulation of speci®c activity. Therefore, the FGFR1 may potentiate growth in normal and malignant melanocytes through activation of Srcmember kinases. An analogous situation exists in ®sh melanocytes expressing high activity of a receptor kinase from the EGFR (epidermal growth factor receptor) family known as Xmrk (Xiphophorus melanoma receptor kinase), responsible for the formation of hereditary malignant melanoma in this ®sh. Xmrk was found in complex with Xfyn and stimulation of the receptor kinase paralleled an increase in Xfyn activity (Wellbrock et al., 1995) . Furthermore, synergism between c-Src and the EGFR in mediating tumorigenesis of human breast and lung cancers expressing high levels of EGFR was suggested to exist since co-expression of receptor and ligand in murine ®broblasts accelerated DNA synthesis, growth in soft agar, and conferred the ability to grow as tumor in nude mice (Maa et al., 1995) . The mechanism by which the FGFR activates the Src kinase is not yet understood. The activity of all Src-family members is positively or negatively regulated by phosphorylation of tyrosyl-residues localized at strategic sites (Courtneidge, 1994) . Direct action of the FGFR kinase on Src was implied in studies showing binding between the FGFR1 and c-Src in aFGF/FGF1 activated NIH3T3 cells (Zhan et al., 1994) . However, although changes in Src phosphorylation in response to bFGF have been observed in other cellular systems, such as lung capillary endothelial cells and murine ®broblasts, no association between the receptor and the kinase could be detected (Landgren et al., 1995) . An alternative mechanism is the integration of the transduced signal within the focal adhesion complex in which the FGFR1, phosphorylated c-Src-and other growth factor receptors and signaling molecules (such as pp125 FAK , phosphatidylinositol-3, phospholipase C-g) co-localize and become associated with the cytoskeleton framework (Plopper et al., 1995) .
Material and methods

Construction of a dominant negative mutant¯g (pSVdn¯g)
We constructed a eucaryotic expression vector encoding the truncated form of mouse fgfr1/¯g that lacks most of the tyrosine kinase domain. The truncated fgfr1/¯g cDNA (dn¯g) was cloned by PCR from a cDNA library of mouse ®broblasts and contained the nucleotide sequence for the three immunoglobulin-like domains of the extracellular region, the transmembrane domain and the 34 amino acids of the intracellular juxtamembrane region (nucleotides 1 ± 1520 of mouse¯g) inserted into the pLSV vector under the transcriptional control of the SV40 early promoter (designated pSVdn¯g).
Cell culture, transfection, proliferation and tumorigenic assays
The ability of the pSVdn¯g plasmid to inhibit a constitutively active FGF-receptor was tested on NIH3T3 cells expressing a chimeric secreted basic ®broblast growth factor (spbFGF-NIH3T3) (Rogelj et al., 1988; Yayon and Klagsbrun, 1990b ) and on human melanoma cells spontaneously expressing bFGF . The spbFGF-NIH3T3 cells expressing bFGF fused to an immunoglobulin signal peptide sequence undergo autocrine transformation evidenced in vitro and are highly tumorigenic and metastatic in vivo (Yayon and Klagsbrun, 1990a,b) . spbFGF-NIH3T3 cells were co-transfected at 20:1 ratio with the pSVdn¯g and a plasmid carrying the hygromycin B resistance gene by either electroporation or by encapsulation in the lipofection reagent DOTAP (Boehringer Mannheim, Germany, following the manufacturer's instruction) and clones were isolated after growth in hygromycin (400 ± 800 mg/ml).
Five dierent metastatic human melanoma cell lines were used in these studies. Three lines are MET + and KIT + (501 mel, 888 mel and 697 mel) and the other two are MET + and KIT 7 (586 mel and YU SIT1) (see Funasaka et al., 1992; Zakut et al., 1993) . The human metastatic melanoma cell lines were maintained in Ham's F10 medium supplemented with 200 U/ml penicillin, 100 mg/ml streptomycin (Gibco/ BRL Laboratories, Grand Island, NY) plus fetal calf and calf serum as described (Zakut et al., 1993) . The cells were co-transfected at 20:1 ratio with pSVdn¯g and pSVneo plasmid DNAs using the DOTAP lipofection reagent and clones resistant to geneticin were selected in 400 ± 800 mg/ml G418 (Gibco). For proliferation assays, cells were seeded in 12-well cluster plates (*3000 cells/cm 2 ) and grown in sets of duplicate wells in medium with or without neomycin (G418). Normal human melanocytes were grown from newborn foreskins as described (BoÈ hm et al., 1995) .
To assess tumorigenicity, NIH3T3 parental and transduced cells were injected subcutaneously (1610 6 cells/ injection site) into a single site of male BALB/c nude mice (5 weeks old, 6 mice/cell type), whereas parental and transduced melanoma cells were injected subcutaneously at the same dose into each¯ank of 5 weeks old male BALB/c nude mice (3 mice/cell type). The mice were housed in laminar¯ow cabinets under pathogen-free conditions and inspected every 4 ± 6 days for tumor growth which was assessed by measuring the tumor size with a ruler.
Cross linking and ligand-dependent dimers and heterodimers
Binding, chemical cross linking and visualization of high anity ligand-receptor complexes were as described (Li et al., 1994a; Yayon et al., 1993; Yayon and Klagsbrun, 1990b) . Brie¯y, for binding activity, cells (50 000/well, 24-well plate) were washed twice with ice-cold PBS and incubated with [ 125 I]bFGF (10 ng/ml) in DMEM containing 1 mg/ml BSA and 25 mM HEPES (pH 7.4) for 2 h at 48C. The cells were then washed twice with ice-cold PBS and twice with ice-cold 1.6 M NaCl (pH 7.4). High anity receptor bound [ 125 I]bFGF was extracted with 20 mM acetic acid/0.15 M NaCl, pH 4.0 and radioactivity determined in a gamma counter. Non-speci®c binding was determined by including a 100-fold excess of unlabeled bFGF in the binding buer.
For anity labeling with [ 125 I]bFGF, the con¯uent monolayers of cells in 6-well plates were washed twice with ice-cold PBS and incubated with [ 125 I]bFGF (10 ng/ml) in DMEM containing 1 mg/ml BSA and 25 mM HEPES (pH 7.4) for 2 h at 48C. The cells were then washed twice with ice-cold PBS, twice with 1.6 M NaCl (pH 7.4) and incubated with the cross linker DSS (disuccinimidyl suberate, 0.15 mM in PBS) or its noncleavable, membrane impermeable, water soluble analog BS 3 (Bis [sulfosuccinimidyl]suberate, 0.5 mg/ml in PBS) (both from Pierce, Rockford, USA) for 30 min at room temperature. The cross-linking reaction was terminated by incubation with PBS containing 150 mM glycine HCl (pH 7.5) for 5 min. The cells were lysed in 0.5% Nonidet-P40/0.15% NaCl/50 mM HEPES (pH 7.4) plus the proteinase inhibitors PMSF (0.4 mM), leupeptin (10 mg/ml) and aprotinin (10 mg/ml). Unsolubilized material was removed by centrifugation at 14 000 r.p.m (15 min, 48C), the cleared lysate was boiled in SDS sample buer and resolved by 5% or 7.5% SDS ± PAGE, followed by autoradiography.
Human FGFR and dn¯g gene expression
We used RT ± PCR (reverse-transcription polymerase chain reaction) to determine the expression of the host human FGFR1 and the murine dn¯g mRNAs relative to bactin mRNA in parental and transduced melanoma cells. The amino acid sequences of mouse and human FGFR1 are almost identical, but the two diverge at the nucleotide level and thus, the presence of the mouse gene transcripts in human cells can be veri®ed by dierential ampli®cation and sequencing of RT ± PCR products. Since the endogenous levels of FGFR1 in human melanomas is extremely low, we ®rst ampli®ed a *1 kb fragment and then used nested primers for further ampli®cation. Primer pairs (*22 mer each), synthesized by the Yale oligonucleotide synthesis core facility, were selected based on sequences of the respective genes ( Table 1 ). The backward primer 5'-CTCGAGTCAGGGATCC-3' from the linker site to the pLSV vector that included the BamHI site of murine¯g at position 1520 was used to selectively amplify dn¯g mRNA. Total RNA was extracted with 4 M guanidine thiocyanate, followed by phenol-chloroform extraction and ethanol precipitation. RNA (5 ± 10 mg) was ®rst annealed with the downstream anti-sense primer and then reverse-transcribed with 200 U M-MLV reverse transcriptase (SuperScript RT, GibcoBRL) for 1 h at 378C, followed by ampli®cation for 25 cycles in the presence of 50 pmoles of sense-and anti-sense primers with 20 U of Ampli-Taq polymerase (Perkin Elmer, Norwalk, CT). Ampli®cation was carried out for 1 min at 958C, 1 min at 558C and 3 min at 728C. The reaction products were electrophoresed on a 2% agarose gel, stained with ethidium bromide and visualized with u.v. light. To substantiate that the PCR products corresponded to the intended segments of targeted cDNA, ampli®ed fragments were puri®ed and sequenced by the DNA sequencing service at the Boyer Center for Molecular Medicine, Yale University School of Medicine.
Western immunoblotting; immunoprecipitation and antibodies
For Western blotting, lysates containing equal amounts of protein (*40 mg/lane, measured by the BioRad protein assay (Bio-Rad Laboratories, Richmond, CA) were subjected to polyacrylamide gel electrophoresis (PAGE) and transferred to PVDF membrane using standard protocols. Membranes were immunoblotted with the indicated antibodies and antigen-antibody complexes were detected by Enhanced Chemiluminescence (ECL, Amersham, Arlington Heights, IL) following the manufacturer's instructions. The following antibodies were used: Monoclonal antibody 4G10 against phosphotyrosine (aPY; UBI, Upstate Biotechnology, Inc., Lake Placid, NY); Src-2-rabbit polyclonal antibody raised against a peptide corresponding to amino acids 509 ± 533 mapping at the carboxy terminus of Src p60 (Santa Cruz Biotechnology, Santa Cruz, CA), reactive with p60 c-Src, p62 c-Yes and p59 c-Fyn; anti-c- , were included in all PAGE analyses. They were: Myosin, b-galactosidase, phosphorylase b, bovine serum albumin, ovalbumin, carbonic anhydrase, soybean trypsin inhibitor and lysozyme.
Immune complex kinase
Normal human melanocytes and melanoma cell were incubated overnight in chemically de®ned medium (PC-1, Whittaker Bioproducts, Walkersville, MD) without serum. The melanoma cells were harvested without any further treatment. The normal melanocytes were harvested before or after stimulation with bFGF (10 ng/ml) or HGF/SF (40 ng/ml, used for comparison) for 15 min. Cells were washed twice with PBS supplemented with 0.1 mM Na 3 VO 4 and 37 mM phenylarsine oxide (Sigma) and harvested in lysis buer containing protease and phosphatase inhibitors (10 mM Tris-HCl pH 7.2, 10 mM NaCl, 10 mM b-glycerolphosphate, 2 mM MgCl 2 , 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM Na 3 VO 4 , 0.4 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin). Extracts containing 500 mg protein were subjected to immunoprecipitation with the indicated antibody employing azide-free conditions. After 1 h incubation with the antibody and A/G PLUS-agarose beads (Santa Cruz), the bound antibody/antigen complexes were washed twice in lysis buer and once in kinase buer (30 mM HEPES pH 7.6, 1 mM DTT, 1 mM benzamidine, 10 mM MgCl 2 ). They were then incubated with 10 mg of the synthetic peptide Raytide (Oncogene Science, Inc, Manhasset, NY) used as a substrate in 30 ml kinase buer supplemented with 5 mM ATP and 5 mCi [g-32 P]ATP (3000 Ci/mmol, NEN Research Products, Boston, MA), for 10 min at 308C. The assays were terminated by spinning the reaction mixtures for 30 s and blotting 10 ml of the supernatants onto 162 cm phosphocellulose strips (Whatman P81). The strips were then air dried, rinsed 46 in 0.5% phosphoric acid, and the radioactivity measured in a liquid scintillation counter. Immunoprecipitation with control rabbit IgG was included for each cell type (negative control). The phosphotransferase values of the negative controls were subtracted from the experimental for each condition.
